Patents Assigned to The Rockefeller University
  • Patent number: 11931164
    Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: March 19, 2024
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventor: Daniel Gareau
  • Patent number: 11918631
    Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 5, 2024
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: David Bikard, Luciano Marraffini
  • Patent number: 11919945
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: March 5, 2024
    Assignee: The Rockefeller University
    Inventor: Michel Nussenzweig
  • Patent number: 11897940
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 13, 2024
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11865094
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: January 9, 2024
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nora Pencheva
  • Publication number: 20240002480
    Abstract: This disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. The disclosed anti-TBEV antibodies represent a novel therapeutic strategy for preventing or treating diseases or infections caused by various tick-borne flaviviruses, including TBEV.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Patent number: 11827911
    Abstract: The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 28, 2023
    Assignee: The Rockefeller University
    Inventors: Vincent A Fischetti, Anu Daniel, Chad Euler
  • Publication number: 20230365661
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 16, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 11808702
    Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: November 7, 2023
    Assignee: The Rockefeller University
    Inventors: Alipasha Vaziri, Siegfried Weisenburger
  • Publication number: 20230338314
    Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 26, 2023
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Masoud Tavazoie
  • Publication number: 20230338505
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 26, 2023
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Publication number: 20230331824
    Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 19, 2023
    Applicants: The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
    Inventors: Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
  • Publication number: 20230295306
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 21, 2023
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 11760805
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: September 19, 2023
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Jeffrey V. Ravetch, Rony Dahan
  • Publication number: 20230279082
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11690905
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: July 4, 2023
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Patent number: 11674952
    Abstract: Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 13, 2023
    Assignee: The Rockefeller University
    Inventors: Ali Brivanlou, Albert Ruzo, Alessia Deglincerti, Tomomi Haremaki, Fred Etoc
  • Publication number: 20230157626
    Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
    Type: Application
    Filed: January 24, 2023
    Publication date: May 25, 2023
    Applicant: The Rockefeller University
    Inventor: Daniel GAREAU
  • Publication number: 20230152561
    Abstract: A multiplexing module provided herein is configured to perform operations of receiving a plurality of laser pulses from a pulsed laser source; splitting each laser pulse into a plurality of beamlets; introducing a delay between each adjacent beamlet of the plurality of beamlets, such that the plurality of beamlets associated with a respective laser pulse of the plurality of laser pulses is distributed equally across a pulse repetition period associated with the pulsed laser source; changing a divergence of each subsequent beamlet of the plurality of beamlets associated with each respective laser pulse to introduce a distinguishing feature between each beamlet of the plurality of beamlet to cause each beamlet to focus on a different axial plane or lateral position of the sample; and outputting the plurality of beamlets associated with each respective laser pulse.
    Type: Application
    Filed: January 31, 2021
    Publication date: May 18, 2023
    Applicant: The Rockefeller University
    Inventors: Alipasha VAZIRI, Jeffrey Dakin DEMAS
  • Patent number: 11649276
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: May 16, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf